X

Drug Profile

Research programme: histone and peptide based therapeutics - SymbioTec

Alternative Names: rhH1 x; rhH1.x

Latest Information Update: 25 Jan 2012

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SymbioTec
Class Peptides; Proteins
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Cancer

Most Recent Events

16 Jan 2012 SymbioTec has been acquired by Xenetic Biosciences
09 Jul 2010 No development reported - Preclinical for Cancer in Germany (unspecified route)
24 Apr 2007 Preclinical trials in Acute myeloid leukaemia in Germany (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com